Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.

SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in an experimental medicine fMRI study and demonstrated excellent safety in Phase 1 multiple-ascending dose clinical trials. The present study was a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12-week, dose escalation study of SRX246 in early symptomatic Huntington's disease (HD) patients with irritability.

Augmenting Human Performance in Remotely Piloted Aircraft.

Introduction: An experiment in a program of research supporting the sense-assess-augment (SAA) framework is described. The objective is to use physiological measures to assess operator cognitive workload in remotely piloted aircraft (RPA) operations, and provide augmentation to assist the operator in times of high workload. In previous experiments, physiological measures were identified that demonstrate sensitivity to changes in workload.